Answers are grounded in this paper and cite their sources.
Protein phosphorylation is a rapid and reversible posttranslational modification that regulates virtually every aspect of renal cell biology. Mass spectrometry-based phosphoproteomics now enables simultaneous measurement of thousands of phosphorylation sites, providing signaling information that transcriptomics or conventional proteomics alone cannot capture. However, the principal challenge has shifted from phosphosite detection to biological interpretation. Disease-associated phosphorylation may reflect altered kinase activity, phosphatase activity, substrate abundance, cellular composition, or compensatory signaling, and most identified phosphosites remain incompletely assigned to their upstream kinases. This narrative review examines how renal phosphoproteomics can progress from descriptive phosphosite inventories toward functional reconstruction of kinase activity. We discuss methodological principles for kinase inference and critically evaluate phosphoproteomic evidence in acute kidney injury, chronic kidney disease, renal fibrosis, diabetic kidney disease, and glomerular disorders. Individual phosphoproteomic studies have identified temporally organized phosphorylation networks during acute kidney injury, persistent inflammatory signaling during maladaptive repair, and JUN-associated signaling in fibrosis. In diabetic kidney disease, a single urinary extracellular vesicle phosphoproteomic study reported altered phosphorylation of GSK3β at Tyr216 and aquaporin 2 at Ser256. Additional studies have characterized phosphorylation of proteins involved in maintaining the glomerular filtration barrier. Integrating kinase substrate databases, spatial and single-cell molecular maps, and functional perturbation may help distinguish causal kinase-dependent signaling from secondary phosphorylation changes. Ultimately, converting the renal phosphoproteome into spatially and temporally resolved kinase activity maps may facilitate mechanistic discovery, biomarker development, drug repurposing, and precision targeting of signaling pathways in kidney disease.
No takes yet. Share an insight, caveat, or question.
Delrue et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: